Skip Navigation LinksHome > July 2013 - Volume 17 - Issue 3 > Hybrid Capture II Testing for High-Risk Human Papillomavirus...
Journal of Lower Genital Tract Disease:
doi: 10.1097/LGT.0b013e31826cd7c1
Original Articles

Hybrid Capture II Testing for High-Risk Human Papillomavirus DNA in the Follow-up of Women Treated for High-Grade Cervical Intraepithelial Neoplasia

Tan, Jeffrey H.J. MBBS, FRANZCOG1,2; Garland, Suzanne M. MBBS, FRCPA, FAChSHM, FANZCOG Ad Eundem1,3,4; Tabrizi, Sepehr N. PhD1,3,4; Moore, Elya E. MS, PhD3,4; Danielewski, Jennifer A. PhD3,4; Quinn, Michael A. MBChB, MGO, MRCP(UK), FRCOG, FRANZOG, CGO1,2

Collapse Box

Abstract

Objective: This study aimed to estimate and compare the validity of high-risk human papillomavirus DNA (HR-HPV DNA) testing using Hybrid Capture II with and without Pap cytological examination in the detection of incident high-grade cervical intraepithelial neoplasia (CIN 2+) after treatment.

Materials and Methods: A total of 1,608 women undergoing ablative or excisional treatment were recruited to the study between May 2001 and June 2005, of whom 985 women were treated for CIN 2+. High-risk HPV DNA tests and Pap smears were performed once in every 6 months for 24 months after treatment.

Results: A total of 888 women were eligible for analysis. High-grade cervical intraepithelial neoplasia was detected in 22 women (2.5%) for the 24 months after treatment. The sensitivity for CIN 2+ detection with cytological diagnosis ranged from 43% to 100%, from 67% to 100% for HR-HPV DNA test, and from 67% to 100% for both tests combined. The specificity of cytological diagnosis ranged from 94% to 97%, from 75% to 84% for HR-HPV DNA test, and from 80% to 82% for both tests combined. The positive predictive value for cytological diagnosis ranged from 8% to 30%, from 4% to 14% for HR-HPV DNA test, and from 4% to 11% for both tests combined. The negative predictive value was 99% or greater for cytological diagnosis alone, HR-HPV DNA test alone, or for both tests combined.

Conclusions: As histologically proven CIN 2+ after treatment for this group of women was low, adding HR-HPV DNA testing to Pap smear did not increase the detection of CIN 2+ or enhance the negative predictive value of cytological diagnosis alone.

Copyright © 2013 by the American Society for Colposcopy and Cervical Pathology

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.